C2N Diagnostics announced a partnership with the Michael J. Fox Foundation to investigate biological connections among Parkinson’s disease, Lewy body dementia, and Alzheimer’s disease. According to the company, the collaboration will focus on measuring key protein biomarkers in blood samples.
The company said it will analyze markers including beta-amyloid, tau, alpha-synuclein, and neurofilament light chain using its proprietary mass spectrometry platform. C2N Diagnostics claims this approach could help identify shared and distinct biological signatures across the three conditions.
The company also said the work will use samples and clinical data from the Parkinson’s Progression Markers Initiative, a long-term study supported by the Michael J. Fox Foundation. According to C2N Diagnostics, integrating biomarker data with clinical observations may improve understanding of disease mechanisms and progression.
C2N Diagnostics claims the findings could inform future diagnostic tools and therapies aimed at neurodegenerative disorders that affect millions worldwide. The company said it plans to share results with the research community as analyses are completed.
